Marileila Varella‐Garcia

Research interests

Publications

• Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz131

• Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

  Journal of Thoracic Oncology · 2015 · 10.1097/jto.0000000000000516

• An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

  Cancer Discovery · 2015 · 10.1158/2159-8290.cd-15-0443

• Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

  JAMA · 2014 · https://doi.org/10.1001/jama.2014.3741

• Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1406766

• Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

  Nature Medicine · 2013 · 10.1038/nm.3352

• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70344-3

• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.2405

• Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-12-0550

• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-11-2906

• Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70232-7

• Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

  Science Translational Medicine · 2011 · 10.1126/scitranslmed.3002442

• Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

  Clinical Cancer Research · 2010 · 10.1158/1078-0432.ccr-10-0851

• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2010 · 10.1056/nejmoa1006448

• Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.19.1635

• Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.17.0530

• ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

  Journal of Thoracic Oncology · 2009 · 10.1097/jto.0b013e3181c4dedb

• KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-3043

• Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2006.07.2587

• Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2006 · 10.1200/jco.2006.06.3958

• Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

  JNCI Journal of the National Cancer Institute · 2005 · 10.1093/jnci/dji112

• Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.01.2823

• IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.09.111

• Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.11.069

• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification

  Blood · 2000 · 10.1182/blood.v95.5.1758.005a41_1758_1766

Current projects

No projects listed.